Clinical trials for OBSOLETE: Inherited retinal disorder
22 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGPHASE1, PHASE2NCT07408232A Phase 1/2 Study in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa (RHO-adRP)Octant, Inc.
- RECRUITINGEarly Phase 1NCT07063030A Study of LX107 Gene Therapy in AIPL1-IRD PatientsShanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- RECRUITINGPHASE1, PHASE2NCT06852963A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001PYC Therapeutics
- RECRUITINGPhase 1NCT06319872The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal DegenerationUniversity of Rochester
- RECRUITINGPhase 1NCT06936787An Open-label, Dose-ascending Study of IGT001 for Retinitis PigmentosaShanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- ENROLLING BY INVITATIONNCT07056738Prospective Exploratory Cohort Study on Ganglion Cell Degeneration in Retinitis Pigmentosa PatientsUniversity Medical Center Goettingen · PI: Emilie Macé, Professor
- ACTIVE NOT RECRUITINGPhase 3NCT06388200A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis PigmentosaOcugen · PI: Huma Qamar
- RECRUITINGPhase 1NCT06455826MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)PYC Therapeutics
- RECRUITINGEarly Phase 1NCT06292650Safety and Efficacy Study of Novel Gene Therapy ZM-02 for Retinitis Pigmentosa PatientsZhongmou Therapeutics · PI: Wenbin Wei, PhD
- ACTIVE NOT RECRUITINGNCT06162585Non-Interventional Long Term Follow-up Study of Participants Previously Enrolled in the RESTORE StudyNanoscope Therapeutics Inc. · PI: Samuel Barone, MD
- ACTIVE NOT RECRUITINGNCT06323772Natural History Study in Patients with PDE6A-, PDE6B- and RHO-linked Retinitis PigmentosaUniversity Hospital Tuebingen · PI: Katarina Stingl, Prof
- ACTIVE NOT RECRUITINGPhase 3NCT05926583A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis PigmentosaJanssen Pharmaceutical K.K. · PI: Janssen Pharmaceutical K.K., Japan Clinical Trial
- RECRUITINGEarly Phase 1NCT05805007Safety and Tolerability Study of Gene Editing Drug ZVS203e in Participants With Retinitis PigmentosaPeking University Third Hospital · PI: Liping Yang, MD
- RECRUITINGPhase 1NCT06291935Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 GeneVeonGen Therapeutics GmbH · PI: Katarina Stingl
- ENROLLING BY INVITATIONNCT05921162A Long-Term Follow-Up Study in Subjects Who Received vMCO-I Administered Via Intravitreal InjectionNanoscope Therapeutics Inc. · PI: Samarendra Mohanty
- RECRUITINGPHASE1, PHASE2NCT05748873Promising ROd-cone DYstrophy Gene therapYSparingVision
- RECRUITINGPhase 1NCT05147701Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for NAIONThe Foundation for Orthopaedics and Regenerative Medicine · PI: Chadwick Prodromos, MD
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05203939Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital AmaurosisOcugen · PI: Huma Qamar, MD, MPH, CMI
- ACTIVE NOT RECRUITINGN/ANCT04285398Prospective Natural History Study of Retinitis PigmentosaSparingVision · PI: Isabelle Audo, MD, PhD
- ACTIVE NOT RECRUITINGPhase 1NCT03999021FIGHT-RP 1 Extension StudyJohns Hopkins University · PI: Peter Campochiaro
- RECRUITINGNCT02471287Genetics of Inherited Eye DiseaseNational Eye Institute (NEI) · PI: Laryssa A Huryn, M.D.
- ACTIVE NOT RECRUITINGPhase 1NCT01736059Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for RetinopathyUniversity of California, Davis · PI: Susanna s Park, MD PhD